New AI Framework Helps Researchers Design Peptides That Turn Cellular Signals On or Off
Scientists use artificial intelligence to create new peptide candidates and predict specific peptide properties. Combining these two abilities in…
-
-
FDA Accepts Generic Tirzepatide Applications for Diabetes and Weight Management
The Food and Drug Administration accepted two generic tirzepatide applications from a major pharmaceutical company. This candidate medication acts…
-
Shame and Stigma Affect the GLP-1 Treatment Journey
Weight stigma has a measurable impact on clinical outcomes during pharmacological treatment for obesity. Glucagon-like peptide-1 receptor agonists, like…
-
The New GLP-1 Pill: What High Performers Need to Know
The arrival of oral GLP-1 pills marks a massive change in how we treat obesity and type 2 diabetes….
-
Oura Ring 5 Launches With Blood Pressure Monitoring and GLP-1 Medication Tracking
Oura recently unveiled the Oura Ring 5. This redesigned wearable introduces clinical features within a significantly reduced form factor….
-
Regulatory Support for Oral Semaglutide and the Evolution of Obesity Therapeutics
The Committee for Medicinal Products for Human Use gave a positive opinion on May 22, 2026. This recommendation supports…
-
EMA Recommends Approval of Oral Wegovy, Positioning Semaglutide as Europe’s First Weight-Loss Pill
The European Medicines Agency recently recommended the approval of a daily weight loss pill. This medication uses semaglutide to…
-
Regulatory Clearance Granted for Initial Human GLP-1 Gene Therapy Trial
Health authorities authorized the first-in-human clinical trial of a GLP-1 gene therapy. This decision marks a significant shift in…
-
Novo Nordisk Advances Oral Semaglutide and CagriSema
Novo Nordisk starts a commercial and clinical comeback. Over the last two years, the company’s market worth has significantly…
-
FDA Approves Orforglipron (Foundayo): First Non-Peptide Oral GLP-1 Receptor Agonist for Chronic Weight Management
The Federal Food and Drug Administration approved orforglipron on April 1, 2026. This landmark decision changes how doctors treat…
